Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02984384 · ClinicalTrials.gov registry record · Phase 3

PREVENTion of Clot in Orthopaedic Trauma

A Phase 3 study, sponsored by Major Extremity Trauma Research Consortium.

Completed
Registry status
Phase 3
Development phase
12,424
Enrollment target

NCT02984384 is a Phase 3 study that has completed, run by Major Extremity Trauma Research Consortium. The registered enrollment target is 12,424 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02984384, a Phase 3 study, has completed, sponsored by Major Extremity Trauma Research Consortium.

COMPLETED
Registry status
Phase 3
Development phase
12,424 participants
Enrollment target

Study Summary

The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.

Interventions

  • DRUG Acetylsalicylic acid
  • DRUG Low Molecular Weight Heparin (LMWH)

Trial Details

FieldValue
Enrollment Target 12,424 participants
Start Date 2017-04-24
Est. Completion 2022-02-18
Phase Phase 3

What the Registry Record Tells You About NCT02984384

The ClinicalTrials.gov registry entry for NCT02984384 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12,424 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Major Extremity Trauma Research Consortium, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Acetylsalicylic acid is the first listed.

NCT02984384 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02984384 about?

NCT02984384 is a clinical study titled "PREVENTion of Clot in Orthopaedic Trauma". The purpose of this study is to compare aspirin versus low-molecular weight heparin (LMWH) (Enoxaparin) as a thromboprophylaxis in patients who sustain a fracture.

What is the current status of trial NCT02984384?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 12,424 participants. The study started on 2017-04-24. Estimated completion is 2022-02-18.

What interventions are being tested in trial NCT02984384?

The interventions under investigation include: Acetylsalicylic acid (DRUG), Low Molecular Weight Heparin (LMWH) (DRUG).

Who is sponsoring clinical trial NCT02984384?

This trial is sponsored by Major Extremity Trauma Research Consortium, which has 30 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.